Want to see HK:1069 full AI Analyst Report?
Top Page
China Bozza Development Holdings Limited
(1069)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$0.29
▼(-36.09% Downside)
Action:Reiterated
Date:07/07/26
The score is primarily held back by weak financial performance driven by high leverage, uneven earnings quality (negative EBIT/EBITDA despite positive net income), and inconsistent free cash flow. Technicals are mixed with modest near-term strength but negative MACD and longer-term moving-average weakness. Valuation is a relative positive due to the very low P/E, but it is offset by the higher-risk financial profile and no dividend yield provided.
Positive Factors
Revenue growth momentum
A strong revenue rebound in FY2025 indicates the company can regain scale after prior losses. Durable top-line expansion supports better fixed-cost absorption, creates optionality for margin recovery, and provides base demand to service debt or reinvest over the next several quarters.
Negative Factors
High leverage / refinancing risk
Heavy leverage constrains financial flexibility and raises refinancing risk in a cyclical industry. Sustained high debt levels increase interest burdens and limit the firm's ability to invest or absorb downturns, making multi-quarter recovery contingent on deleveraging.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth momentum
A strong revenue rebound in FY2025 indicates the company can regain scale after prior losses. Durable top-line expansion supports better fixed-cost absorption, creates optionality for margin recovery, and provides base demand to service debt or reinvest over the next several quarters.
Read all positive factors
China Bozza Development Holdings Limited (1069) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$92.63M
Dividend YieldN/A
Average Volume (3M)417.79K
Price to Earnings (P/E)0.9
Beta (1Y)1.08
Revenue Growth56.25%
EPS Growth496.46%
CountryHK
Employees29
SectorBasic Materials
Sector Strength58
IndustryPaper, Lumber & Forest Products
Share Statistics
EPS (TTM)0.28
Shares Outstanding308,772,670
10 Day Avg. Volume214,500
30 Day Avg. Volume417,794
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.30
Price to Sales (P/S)0.33
P/FCF Ratio-33.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Bozza Development Holdings Limited Business Overview & Revenue Model
Company Description
China Health Technology Group Holding Co., Ltd. functions as an investment firm, concentrating its efforts on forestry management. Its activities include the cultivation, felling, and commercialization of timber goods. The organization was establi...
How the Company Makes Money
null...
China Bozza Development Holdings Limited Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
28
Negative
Cash Flow
52
Neutral
| Breakdown | TTM | Jun 2024 | Jun 2024 | Dec 2022 | Jun 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 94.60M | 97.39M | 47.61M | 58.72M | 6.76M | 6.67M |
| Gross Profit | 8.62M | 8.87M | 1.90M | 11.51M | 0.00 | 6.67M |
| EBITDA | -7.74M | -7.74M | 208.39M | -42.17M | -9.85M | -48.36M |
| Net Income | 24.03M | 24.52M | 200.01M | -10.80M | -18.90M | -268.54M |
Balance Sheet | ||||||
| Total Assets | 225.04M | 191.09M | 178.17M | 140.64M | 93.52M | 491.54M |
| Cash, Cash Equivalents and Short-Term Investments | 4.92M | 2.68M | 3.23M | 4.33M | 1.11M | 134.00K |
| Total Debt | 127.45M | 115.23M | 119.11M | 356.77M | 321.97M | 333.44M |
| Total Liabilities | 173.86M | 166.22M | 165.20M | 457.35M | 400.15M | 369.48M |
| Stockholders Equity | 51.18M | 24.87M | 12.96M | -316.71M | -306.63M | 122.06M |
Cash Flow | ||||||
| Free Cash Flow | 1.77M | -959.71K | 28.63M | 22.16M | -466.00K | -5.58M |
| Operating Cash Flow | 37.09M | 37.43M | 28.86M | 23.44M | -466.00K | -5.58M |
| Investing Cash Flow | -37.63M | -38.34M | -26.49M | -23.26M | 2.00K | -410.00K |
| Financing Cash Flow | 1.96M | 2.29M | -3.47M | 3.04M | -249.00K | -3.29M |
China Bozza Development Holdings Limited Technical Analysis
Positive
0.46
Price Trends
0.27
Positive
0.29
Positive
0.32
Negative
Market Momentum
<0.01
Negative
63.14
Neutral
74.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1069, the sentiment is Positive. The current price of 0.46 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.27, and above the 200-day MA of 0.32, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.14 is Neutral, neither overbought nor oversold. The STOCH value of 74.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1069.
China Bozza Development Holdings Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$16.41B | 6.60 | 7.88% | 3.95% | 13.69% | 83.56% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
57 Neutral | HK$32.85B | 8.54 | 7.39% | ― | 7.38% | 252.52% | |
56 Neutral | HK$862.77M | 5.14 | 3.27% | 5.15% | -3.12% | -41.12% | |
46 Neutral | HK$92.63M | 0.94 | 44.96% | ― | 56.25% | 496.46% | |
45 Neutral | HK$424.38M | -3.46 | -59.49% | ― | 27.73% | -478.69% | |
24 Underperform | HK$4.35B | -0.77 | -299.18% | ― | -48.87% | 16.69% |
* Basic Materials Sector Average
HK:1069
China Bozza Development Holdings Limited
0.30
-0.10
-24.43%
HK:2314
Lee & Man Paper Manufacturing
3.83
1.04
37.08%
HK:2689
Nine Dragons Paper Holdings
6.97
1.32
23.36%
HK:1812
Shandong Chenming Paper Holdings Co., Ltd. Class H
0.62
-0.32
-33.87%
HK:2002
China Sunshine Paper Holdings Co. Ltd.
0.90
-0.92
-50.55%
HK:0731
C&D Newin Paper & Pulp Corporation Limited
0.30
0.11
58.73%
China Bozza Development Holdings Limited Corporate Events
China Health Technology Group Appoints New Company Secretary and Authorised Representative
Jul 9, 2026
China Health Technology Group Holding Company Limited has appointed Mr. Chow Yun Cheung as its new company secretary and authorised representative, effective 9 July 2026, replacing Mr. Chan Ngai Fan. Mr. Chow, a member of the Hong Kong Institute o...
China Health Technology Group Details Board and Committee Structure
Jun 25, 2026
China Health Technology Group Holding Company Limited has announced the current composition of its board of directors, led by executive director and chairman Bi Xue and chief executive officer Leung Ka Wai, alongside fellow executive director Wong...
China Health Technology Group Reshapes Top Leadership, Names New CEO
Jun 25, 2026
China Health Technology Group Holding Company Limited has reshuffled its top management, with long-serving chief executive officer Bi Xue stepping down from the CEO role while remaining as an executive director and chairman of the board. The move ...
China Health Technology rights issue boosts capital and widens public float
Jun 16, 2026
China Health Technology Group completed a non-underwritten rights issue offering two rights shares for every existing share, expanding its issued share capital from 102.9 million to about 161.8 million shares. Valid applications were received for ...
China Health Technology Corrects Executive’s English Name in Regulatory Filings
May 29, 2026
China Health Technology Group has issued a clarification announcing that the English name of its chairman, chief executive officer and executive director, previously disclosed as “Bu Xue” in corporate documents since August 2023, was a...
China Health Technology reshapes board with executive director change
May 15, 2026
China Health Technology Group Holding Company Limited has announced the resignation of executive director Ms. Cao Xiying, effective 15 May 2026, citing other business commitments and noting no disagreement with the board or issues requiring shareh...
China Health Technology Sets Out Board and Committee Structure
May 15, 2026
China Health Technology Group Holding Company Limited has announced the current composition of its board of directors, led by executive director and chairman cum chief executive officer Ms. Bu Xue, alongside fellow executive and independent non-ex...
China Health Technology Wins Shareholder Backing for Rights Issue and Placing
May 12, 2026
China Health Technology Group Holding Company Limited secured shareholder approval at an extraordinary general meeting on 12 May 2026 for a proposed rights issue and a placing agreement. The resolutions were passed by poll with 100% of votes cast ...
China Health Technology Shifts EGM Venue to Shenzhen, Keeps All Other Arrangements Unchanged
Apr 30, 2026
China Health Technology Group Holding Company Limited has announced a change in the venue for its extraordinary general meeting scheduled for 3:30 p.m. on 12 May 2026, shifting the event to Suite 1702, 17/F, Tower A, Bojin Business Plaza, Chegongm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.